TLDR
- Veru stock surged over 167% after disclosing a formal clinical supply agreement with Novo Nordisk, filed with the SEC on June 4, 2026.
- Novo Nordisk will supply its weight-loss drug Wegovy to Veru at no cost for a Phase 2b clinical trial called PLATEAU.
- The trial tests enobosarm combined with Wegovy in older adults with obesity.
- Novo Nordisk also secured first negotiation rights on any future enobosarm-GLP-1 commercial opportunities.
- Veru stock moved from a previous close of $2.25 to a session high of $6.02, approaching its 52-week high of $7.40.
Veru stock jumped more than 167% in mid-day trading on Thursday after the company disclosed a formal clinical supply agreement with Novo Nordisk, filed with the SEC on June 4, 2026. The stock moved from a prior close of $2.25 to a session high of $6.02.
The agreement, signed June 2, 2026, covers Veru’s ongoing Phase 2b PLATEAU clinical study. The trial is evaluating enobosarm in combination with Wegovy (semaglutide) in older adults with obesity.
Under the terms of the deal, Novo Nordisk will supply Wegovy to Veru at no cost for the duration of the trial. For a small-cap biotech like Veru, that is meaningful cost relief.
As part of the arrangement, Novo Nordisk also received first negotiation rights on any future commercial opportunities involving an enobosarm and GLP-1 combination. Investors read that clause as a strong signal of confidence from the world’s leading GLP-1 franchise.
Trading volume on Thursday dwarfed Veru’s average daily turnover. The move appeared driven by retail and momentum-oriented buyers reacting to the 8-K filing, with the Novo Nordisk name adding credibility to the program.
What the Data Shows
The PLATEAU trial builds on data from the Phase 2b QUALITY study. In that earlier trial, enobosarm combined with semaglutide produced greater fat loss during active weight reduction.
After semaglutide was discontinued in the QUALITY study, enobosarm helped prevent the regain of both weight and fat mass while preserving lean muscle. That combination profile drew attention in the obesity drug space.
The PLATEAU trial is now the next step in testing that combination more broadly. Veru is conducting and sponsoring the study.
Market Context
The broader market on Thursday was mixed. The S&P 500 gained 0.4% and the Dow Jones rose 1.9%, while the Nasdaq slipped 0.2%.
No major Federal Reserve announcements or macroeconomic data releases appear to have materially influenced the session.
Novo Nordisk stock also moved on the news, rising around 4.17% during the session.
Veru’s session high of $6.02 put it close to its 52-week high of $7.40. The stock has nearly tripled in value so far in 2026.
By mid-afternoon Thursday, Veru was trading at approximately $5.74.
Be the first to comment